Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02508532 · OUTCOME

Plasma Drug Concentration at 24 Hours Postdose Prior to the Next Daily Dose (C24)

(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors · Source last updated 2022-06-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
ng/mL
Interval / dispersion
Standard Deviation
Time frame
Cycle 1 Day 1

What was measured

Plasma drug concentration at 24 hours postdose prior to the next daily dose (C24) following a single dose of avapritinib

Analysis population: Patients enrolled in Part 1 or Part 2 with a starting dose of 300 or 400 mg QD and available PK samples

Groups in this outcome

Part 1 and Part 2: Avapritinib (Formerly BLU-285) 300 mg QD

Part 1 and Part 2: Patients received a starting dose of 300 mg QD. Patients received avapritinib in continuous 28 day cycles until discontinuation.

Part 1 and Part 2: Avapritinib (Formerly BLU-285) 400 mg QD

Part 1 and Part 2: Patients received a starting dose of 400 mg QD. Patients received avapritinib in continuous 28 day cycles until discontinuation.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Part 1 and Part 2: Avapritinib (Formerly BLU-285) 300 mg QD36
Part 1 and Part 2: Avapritinib (Formerly BLU-285) 400 mg QD19

Reported measurements

Source class 1
Values in ng/mL · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Part 1 and Part 2: Avapritinib (Formerly BLU-285) 300 mg QD13449.4Not reportedNot reportedNot reported
Part 1 and Part 2: Avapritinib (Formerly BLU-285) 400 mg QD18580.2Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        49.4
        value
        134
      2. group Id
        OG001
        spread
        80.2
        value
        185
denoms
  1. counts
    1. group Id
      OG000
      value
      36
    2. group Id
      OG001
      value
      19
    units
    Participants
description
Plasma drug concentration at 24 hours postdose prior to the next daily dose (C24) following a single dose of avapritinib
dispersion Type
Standard Deviation
groups
  1. description
    Part 1 and Part 2: Patients received a starting dose of 300 mg QD. Patients received avapritinib in continuous 28 day cycles until discontinuation.
    id
    OG000
    title
    Part 1 and Part 2: Avapritinib (Formerly BLU-285) 300 mg QD
  2. description
    Part 1 and Part 2: Patients received a starting dose of 400 mg QD. Patients received avapritinib in continuous 28 day cycles until discontinuation.
    id
    OG001
    title
    Part 1 and Part 2: Avapritinib (Formerly BLU-285) 400 mg QD
param Type
MEAN
population Description
Patients enrolled in Part 1 or Part 2 with a starting dose of 300 or 400 mg QD and available PK samples
reporting Status
POSTED
time Frame
Cycle 1 Day 1
title
Plasma Drug Concentration at 24 Hours Postdose Prior to the Next Daily Dose (C24)
type
SECONDARY
unit Of Measure
ng/mL

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice